Prana Biotechnology today announced that the first patient has been dosed in the “IMAGINE Trial” - 12 month Phase II Imaging trial testing PBT2, the Company’s drug in development for Alzheimer’s Disease.
Prana Biotechnology today announced the publication in the journal PLoS ONE, of an article that strongly endorses PBT2’s potential to treat Alzheimer’s Disease. The paper, entitled “The Zinc Dyshomeostasis Hypothesis of Alzheimer’s Disease”1 presents an integrated explanation of the major pathological features of Alzheimer’s Disease, based upon a combination of new experimental data and mathematical modeling.
Prana Biotechnology today announced that the first patient has been dosed in the “Reach2HD Trial” – a 6 month Phase IIa clinical trial testing PBT2, the Company’s drug in development for Huntington disease. Reach2HD, a double blind placebo controlled study, is enrolling 100 patients with early to mid-stage Huntington Disease. The Principal Investigator on the study is Dr. Ray Dorsey of Johns Hopkins University.
Prana Biotechnology today commented on the publication of new data of relevance to the current clinical trial, testing Prana’s PBT2 as a treatment for Huntington disease.
Prana Biotechnology today announced that Executive Chairman, Geoffrey Kempler is scheduled to present a corporate update at upcoming healthcare conferences in Australia and the US.
Prana Biotechnology today announced that an update on Prana’s Phase 2 clinical trial in Huntington disease (HD) was presented at the HDSA annual National Convention held in Las Vegas, Nevada over the weekend. Professor Ira Shoulson, Professor of Neurology, Pharmacology and Human Science and Director, Program for Regulatory Science & Medicine at Georgetown University spoke to the ‘Reach2HD’ trial objectives and potential future of PBT2 as a novel therapeutic strategy for the treatment of HD.
Prana Biotechnology today advised that Professor Michael Woodward, the National Study Coordinator for the Company’s Alzheimer’s disease IMAGINE trial, will be interviewed by ABC Radio commentator Jon Faine.
Prana Biotechnology today reported on its progress in its Phase II clinical trials with its lead development asset PBT2. PBT2 has a unique therapeutic action that can benefit people suffering neurodegenerative disease because of its specialized ability to prevent the toxic relationship between disease proteins and biological metals in the brain.
Prana Biotechnology Limited, announced today that its lead compound in development for Parkinson’s disease (PD), PBT434, had progressed successfully through a series of preclinical development studies used to assess the suitability of a candidate compound for human clinical studies. The studies were funded by The Michael J. Fox Foundation (MJFF) 2011 Pipeline Program to support its ‘Therapeutic Development Initiative’. The MJFF Program grant is milestone based. PBT434 achieved all of its milestones in preclinical toxicology studies, genotoxicity and safety pharmacology - allowing the compound to be positioned for larger scale animal toxicology studies prior to commencing clinical trials.
Receive news from Alterity Therapeutics
